echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Another Phase 3 clinical failure in the treatment of early-stage breast cancer by Pfizer Ibrace.

    Another Phase 3 clinical failure in the treatment of early-stage breast cancer by Pfizer Ibrace.

    • Last Update: 2020-10-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020.10.10 Research and Development NEWS: ALKS 3831 Therapeutic Fine Points and Bipolar Affective Disorders voted for by the FDA Advisory Committee; AstraZenece's long-acting new coronary antibody begins Phase III clinical trials; Astellas' clinical application for ADC therapy is accepted by CDE; and human medicine La Bellor tablets are approved by the FDA... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
    (click on the title, read the original article) Pfizer Ibrance treatment of early breast cancer another phase 3 clinical failure 9, Pfizer announced that Ibrance in the treatment of HR/ HER2 - early breast cancer in the second large-scale phase 3 clinical study PENELOPE-B failure.
    The study, conducted in patients with HR-/HER2-early breast cancer with a high risk of recurrence after completion of new assisted chemotherapy and tumor excision, assessed the efficacy and safety of 1 year of Ibrace therapy combined with at least 5 years of standard assisted endocrine therapy and placebo combined with at least 5 years of standard assisted endocrine therapy.
    results show that the study did not reach the main endpoint of prolonging the survival of non-invasive diseases.
    AstraZenecon Long-Acting New Coronary Antibodies begin Phase III Clinical Today, AstraZenecon announced that its Long-Acting New Coronary Antibody Portfolio will begin a Phase III clinical trial of prevention for 6,000 people and a Phase III clinical trial for 4,000 people.
    the drug, codenamed AZD7442, is a mixture of two antibodies called COV2-2196 and COV2-2130, which bind to two different bits of the new coronary S protein.
    AZN's acquisition of Vanderbilt University in June to extend its half-life with its own Fc modifications.
    clinical application for ADC therapy submitted by Astellas was accepted by CDE today, CDE announced that Astellas has submitted two clinical trial applications for injection enfortumab vedotin in China.
    , an antibody-coupled drug targeted at Nectin-4 that has been approved by the FDA for breakthrough therapy and priority review, was approved for sale in the U.S. at the end of 2019 for the treatment of patients with locally advanced or metastatic urethra cancer.
    it is worth mentioning that this is the first time the product has been declared clinical in China.
    ALKS 3831 therapeutic fine points and bipolar disorder was voted on by the FDA Advisory Committee on the 9th, Alkermes announced that the FDA-appointed Advisory Committee on Psychopullin and the Advisory Committee on Drug Safety and Risk Management joint meeting for oral atypical antipsychotic drug candidate APKS 3831 (Ao nitrogenpine/samidorphan) for the treatment of adult schizophrenia patients and adult type I bipolar disorder patients to give positive results.
    a joint vote by the Committee on Health and Development that Samidorphan had meaningfully reduced the weight gain associated with the drug (16 yes, 1 no), while the safety of APKS 3831 had been adequately demonstrated (13 yes, 3 no, 1 abstention).
    People's Fu Medicine La Bellor tablets obtained FDA approval number 10, Human Fu Pharmaceuticals issued a notice that People's Fu Pharmaceuticals wholly-owned subsidiary Epic Pharma, LLC received the FDA's approval number for hydrochloric acid la bellore tablets, hydrochloric acid labelol tablets are suitable for various types of hypertension.
    Chenxin Pharmaceuticals Esomeprazole magnesium intestinal capsule approved by the U.S. FDA on the 9th, Chenxin Pharmaceuticals announced that recently received a notice from the U.S. FDA, the company to the U.S. FDA declared the application for a simple new drug for Esomerazole magnesium intestinal capsule has been approved.
    Esomerazole (formerly used to be Esomeprazole) is a single isomer of Omeprazole, belongs to proton pump inhibitors, can effectively consistent gastric acid secretion, clinically used in the treatment of gastroesophageal reflow disease, rotting reflow esophagitis and so on.
    ( Frontiers in Medicine ) NEJM published the final results of the Redsiway Global Trials , showing that the initial results of three major global clinical trials sponsored by the U.S. Institute of Allergy and Infectious Diseases called ACTT-1 showed that Redsyvirus significantly accelerated the recovery time of hospitalized patients with new coronavirus diseases.
    the final report of the ACTT-1 trial was published in the New England Journal of Medicine on October 8.
    South data conveys three important messages: 1) Redsiway accelerates patient recovery; 2) Redsiway reduces the risk of patient progression; and 3) Redsiway shows a trend toward reducing patient mortality throughout the study period.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.